[A19-05] Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2019
Commission awarded on 14.01.2019 by the Federal Joint Committee (G-BA).
Immune system and infections
Adults infected with HIV-1
Added benefit not proven for treatment-naive or pretreated patients
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.